In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 20, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival, according to a study published online May 14 in JAMA Network Open.

Elena J. Ladas, Ph.D., R.D., from the Columbia University Irving Medical Center in New York City, and colleagues examined the association of the duration of overweight or obesity with treatment-related toxic effects, minimal residual disease, relapse, and survival in childhood ALL in a prospective study. Fluctuations in z scores of body mass index for age from diagnosis to end of treatment (EOT) were examined in 794 children (mean age at diagnosis, 6.7 years).

The researchers found an increase in the prevalence of overweight or obesity from diagnosis to EOT, from 29.5 to 48.4 percent. There was no association for having overweight or obesity at baseline or developing overweight or obesity during induction with treatment-related toxic effects or higher minimal residual disease. Compared with children with overweight or obesity at no more than one time point, those with overweight or obesity at two or more time points experienced inferior overall survival, increased relapse, and lower event-free survival. Among children with overweight or obesity at two or more time points, there was an association with an increased risk for death and relapse (hazard ratios, 3.49 and 1.92, respectively).

“Treatment for obesity is evolving, and our study highlights the importance of working closely with children and their families to provide comprehensive care -- whether by treating obesity during therapy or preventing it altogether,” Ladas said in a statement. “Our findings support a new clinical approach that includes proactive nutrition therapy for children undergoing treatment for acute lymphoblastic leukemia.”

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-21 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords